A recent meta-analysis demonstrated that PD-L1 expression is significantly associated with response to anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer.[15] However, a proportion of apparently PD-L1-negative patients also benefits from anti-PD-1 therapy. Here, CD274 is linked to non-small cell lung carcinoma.